Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eight Clinical Trial Read-Outs To Look Out For In Early 2018

Executive Summary

The first three months of the year should bring late-stage clinical trial read-outs for a range of novel products including Johnson & Johnson's esketamine, Esperion's bempedoic acid, ImmuPharma's Lupuzor and VBL's gene therapy for brain cancer.


Related Content

After Bad Data Comes Layoffs – Will The Next Job Cuts Be At Anthera?
10 First Approvals To Look Out For In 2018
Promising Esketamine Remains On Track As Potential Depression Blockbuster
Deal Watch: Genentech Expands Upon Arvinas PROTAC Collaboration
Life In The Old Dog Yet: Growth In Dyslipidemia Market Expected To 2025
Takeda Paves The Way For Myovant With Phase III Fibroid Success
Alzheimer’s Update: Amyloid Hypothesis Lives On At Biogen, Lilly, Merck, Pfizer, Roche
ARMO Rides Immuno-Oncology Wave With $50m For Its PD-1 Booster


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts